Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
|ClinicalTrials.gov Identifier: NCT01270399|
Recruitment Status : Unknown
Verified March 2012 by Meir Medical Center.
Recruitment status was: Recruiting
First Posted : January 5, 2011
Last Update Posted : October 30, 2012
Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed.
Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included).
The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.
|Condition or disease||Phase|
|The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.||Early Phase 1|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Observational Model:||Case Control|
|Official Title:||Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||January 2013|
|malignant neoplasm's cells|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01270399
|Meir Medical Center||Recruiting|
|Kfar Saba, Israel|
|Contact: Maya Gottfried, MD 972-9-7472414 Maya.Gottfried@clalit.org.il|
|Principal Investigator: Maya Gottfried, MD|